|
Setidegrasib Clinical Trials
3 actively recruiting trials across 3 locations
No change since July 2026
Also known as: ASP3082
Pipeline
Phase 1: 1Phase 3: 2
Top Sponsors
- Astellas Pharma Global Development, Inc.2
- Astellas Pharma Inc1
Indications
- Cancer3
- Metastatic Pancreatic Adenocarcinoma1
- Metastatic Pancreatic Cancer1
- Non-small Cell Lung Cancer (NSCLC)1
- Pancreatic Cancer1
Tucson, Arizona1 trial
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
University of Arizona Cancer Center - North Campus
Phase 3
Duarte, California1 trial
A Study of ASP3082 in Adults With Advanced Solid Tumors
City of Hope National Medical Center
Phase 1
Glendale, California1 trial
A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
Oncura Health d.b.a.Los Angeles Cancer Network
Phase 3
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.